Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | MGD013 |
| Synonyms | |
| Therapy Description |
MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MGD013 | MGD-013 | Immune Checkpoint Inhibitor 94 LAG3 Antibody 10 PD-L1/PD-1 antibody 63 | MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | Advanced Solid Tumor | not applicable | MGD013 | Phase I | Actionable | In a Phase I trial, MGD013 treatment resulted in a partial response in 7.3% (3/41) and stable disease in 51.2% (21/41) of response-evaluable patients with advanced solid tumors in the dose escalation cohort (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). | detail... |
| Unknown unknown | ovary epithelial cancer | not applicable | MGD013 | Phase I | Actionable | In a Phase I trial, MGD013 treatment resulted in a partial response in 13.3% and stable disease in 46.7% (7/15) of patients with epithelial ovarian cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). | detail... |
| Unknown unknown | stomach cancer | not applicable | MGD013 | Case Reports/Case Series | Actionable | In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with gastric cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). | detail... |
| Unknown unknown | malignant mesothelioma | not applicable | MGD013 | Case Reports/Case Series | Actionable | In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with mesothelioma (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). | detail... |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | MGD013 | Phase I | Actionable | In a Phase I trial, MGD013 treatment resulted in a partial response in 14.3% (2/14) and stable disease in 35.7% (5/14) of patients with triple-receptor negative breast cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT03219268 | Phase I | MGD013 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Recruiting |
CKB BOOST